Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2008

View Archived Issues

Recent Allergan patent divulges novel antiglaucoma agents

Novel agents for treating allergic disorders disclosed in recent Array patent

Recent patents describe novel antidepressant and antipsychotic agents

ARRY-520 shows less chemoresistance-inducing potential than paclitaxel in vitro

Novel erbB2 inhibitor shows efficacy in different preclinical cancer models

Preclinical profile of Wyeth's novel progesterone receptor modulator

Novel GnRH allosteric modulator discovered at Organon

Vermillion announces positive results from clinical trial of ovarian tumor triage test

Oncolin changes name from Edgeline Holdings and provides update on activities

Ardea presents update on its 2008 plans

Sonus refines strategic initiatives and focuses on development of SN-2310 in cancer

Targeted Genetics reports interim data from phase I/II clinical trial of tgAAC-94

Genentech initiates clinical development in the U.S. and U.K. of cancer drug GDC-0941

Adherex initiates phase III trial of sodium thiosulfate for hearing loss in children

Nventa reports positive interim data from HspE7 phase I cervical dysplasia trial

AEterna Zentaris initiates second phase III trial of cetrorelix for benign prostatic hyperplasia

ExonHit announces results from phase I study of EHT-0202 for brain impairments

Lorus initiates toxicology studies of anticancer drug LOR-253

Oxigene initiates dosing in phase II study of Zybrestat for NSCLC

Roswell Park Cancer Institute awarded USD 900,000 grant for ovarian cancer vaccine

Trubion provides update on product pipeline

European Commission approves novel oral anticoagulant Pradaxa

Positive results for VX-770, Vertex's cystic fibrosis protein modulator

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...